A new post-hoc analysis is set to be presented at the European Congress on Obesity (ECO 2026) evaluating orforglipron in adults aged 65 and older with obesity, stratified by diabetes status. The analysis focuses on efficacy and safety outcomes for the oral GLP-1 receptor agonist across older populations with and without type 2 diabetes. The dataset is positioned to inform how oral incretin-based therapies perform in a group where tolerability and clinically meaningful metabolic changes are key determinants of real-world adoption. Orforglipron’s development program has emphasized convenience versus injectable GLP-1 therapies, and age-specific analyses can influence how clinicians model risk-benefit tradeoffs. Details on magnitude of effect and adverse event rates are not included in the article, but the ECO platform signals a push for clearer guidance in older adults ahead of broader prescribing discussions.